



2026 PVA Healthcare Summit + Expo

Live Conference
August 30 – September 2, 2026
Las Vegas, NV

Continuing Education Information

This continuing education activity is provided by AffinityCE and the Paralyzed Veterans of America (PVA).

Target Audience

This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, pharmacists, psychologists, social workers, occupational therapists, physical therapists, certified rehabilitation counselors and registered dietitians. A statement of participation is available to other attendees.

Course Registration Link: <https://na.eventscloud.com/ereg/newreg.php?eventid=861597>

CE Information: <https://www.summitpva.org/continuing-education>

Learning Objectives

At the end of this activity, participants should be able to:

- Review the best practices management of SCI, MS, and ALS List the clinical benefits of utilizing the VA healthcare system for life-long integrated MS care.
- Identify the administrative structure and oversight requirements of the VHA's artificial intelligence initiatives.
- Summarize current evidence on integrative strategies used in SCI care and identify gaps in how these approaches are incorporated into fellowship training.
- Recognize how caregiver report of depression relates to self-report of suicidal risk.
- Evaluate differences in the frequency and relative impact of reported pain points by mobility device type.
- Determine when to refer individuals with MS for comprehensive neuropsychological assessment or specialized intervention, using provided guidelines.
- Identify the importance of using clinical screening for polysubstance use in the SCI population in their own clinical practice.

- Define the economic benefits of using a home-based sleep screening test (HBSST) in the diagnosis of sleep apnea in individuals living with SCI.
- Discuss the potential of rehabilitative strategies for eye movement dysfunction in MS

Disclosures

AffinityCE staff, PVA staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Faculty disclosures are provided for viewing prior to engagement with program content and stated prior to the start of each presentation.

Dr. Naghmeh Abbasi Kasbi, M.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mr. Izzy S Abbass, MBA

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Hyunseo An, MSOT, Ph.D. Student

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Melodie L. Anderson, DNP, RN, CTC-TP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Margaret Arnold, PT

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Annette Nicole Askren, CScD, CCC-SLP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Ernest John Aucone, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Francesca Bagnato, MD, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mrs. Mandi Bailey, BS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Richard Bedlack, MD, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Beth A. Beenken, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. F Stephen Benesh, MD

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses I will discuss failed trials of various drugs used to treat multiple sclerosis including Cyclophosphamide, rituximab, laquinimod, tolebrutinib, opicinumab

Ms. Kendra Betz, MSPT, ATP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Madelaine Blincoe, BS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Valerie Block, PT, DPTSc.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr Joyce Boyd, DNP, AGNP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Jill Brattain, B.S

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Christine Brown, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Maggi A Budd, Ph.D., MPH, HEC-C, ABPP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Stephen Burns, MD

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mcknight Caitlin, SLP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr Jorge L Candiotti, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Gizelda Tardin Bonamichi Casella, MD Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses: The authors observed that instillation of Renacidin decreased catheter associated urinary tract infection (CAUTI) frequency in neurogenic bladder of SCI subjects. Renacidin is FDA-approved to decrease catheter incrustations and there is no mention about preventing CAUTI.

Shane Chanpimol, PT, DPT, NCS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Vicky Chen, M.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Yuying Chen, Ph.D., MD

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Stacey L. Clardy, MD., Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Robbin Clark, RN, MSN-Ed.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Kathryn Collazos, Ph.D., BSN, RN

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Bridget A. Cotner, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Michael John DeVivo

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Moira Dux, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Douglas Eck, PT, DPT, NCS, MHI, ATP

- Restorative Therapies, Inc: Douglas Eck receives compensation as a contract installer/educator for Restorative Therapies, Inc. He has no ownership interest and performs no sales role for the company.
- No discussion of unapproved drug or product uses.

Miss Bethany Ferguson, LCSW-C, CCM

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mr. Owen Flaugh, M.S.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mr. Martin B Forchheimer, MPP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Julio C Furlan, MD, LLB, MBA, MSc., Ph.D., FRCPC, FAAN

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Chan Gao, M.D., Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Glenn D. Graham, MD., Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses: Artificial intelligence tools in development to enhance mobility, functioning, or communication.

Robert Charles Hand, PT, DPT, NCS, ATP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Juli Harrison, OTD, OTR/L, ATP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

C. Eric Heidorn, Ph.D., MS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Carrie Ann Henry, LCSW

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Ms. Danielle Hetu, MS, CRC, CWIC, VET-C

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Rachel M. Hibbs, DPT, NCS, ATP/SMS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Ms. Pauline (Tony) Hilton, DrPH, RN, MSN, FNP, CRRN, FARN

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Ileana Howard, MD

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Leyla Huseynli, M.D

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mr. Jeffrey P Jaramillo, PT, DPT, MS

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses: We intend to discuss two wheelchairs that are currently not FDA-approved medical devices.

Dr. Melinda S Kavanaugh, Ph.D., LCSW

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Michael Kennelly, MD, FACS

- AbbVie: Researcher, Consultant
- BD: Researcher, Consultant
- Boston Scientific: Researcher, Consultant
- Coloplast: Researcher, Consultant
- Convatec: Consultant
- Cook Myosite: Researcher
- FemPulse: Researcher
- Medtronic: Researcher, Consultant
- Spine X: Researcher
- Sumitomo Pharmaceuticals: Researcher, Consultant
- No discussion of unapproved drug or product uses.

Sarah Kiefer Luhning, M.A., CCC-SLP, ATP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. B. Jenny Kiratli, Ph. D.

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses: We Intend to discuss two non-FDA approved devices wheelchairs.

Virginia May Kudritzki, DPT, CSRS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Ingrid Kwee, MD

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mrs. Darling, Leah, LCSW

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Ashley Lee, MS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Terry Lee-Wilk, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Jennifer Lynn, OTR

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Mark Manago, PT, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Marsha L. Marquez, MSN/ED., RN

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Paige Matijasich, M.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Ms. Mary McDirmid, ChSNC, ChFC

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Paul Mehta, MD

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mr. Daniel S. McPartlin, PA

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses: This presentation will discuss many medications and classes of medications. They will be discussed as part of de-prescribing efforts for inappropriate medications in the setting of SCI, and recommended alternatives. We have attempted to summarize medication classes where off label use MAY be discussed. Please note that none of these off-label uses of medications are being recommended, rather, these medications may have been prescribed for off label uses, and this may be discussed as part of the presentation. Benzodiazepines: anxiety, spasticity. Non-selective beta blockers: anxiety, postural orthostatic tachycardia syndrome. Alpha Blockers; lower urinary tract symptoms, chronic prostatitis, ureteral stent-related urinary symptoms. Fluoroquinolones: surgical prophylaxis, prostatitis, epididymitis, osteomyelitis. NSAIDs: acute gout flare.

Dr. Christine Melillo, Ph.D., RN

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Laura C. Mellon, MS, CCC-SLP, ATP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

MD Anza Bilal Memon, MD

- Connected Research: Consultation
- Genentech: Clinical Research for organization
- TG Therapeutics: Clinical Research for organization
- No discussion of unapproved drug or product uses.

Dr. Ashlyn Mitchell, Psy.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mrs Sahel Moein, M.D, M.Sc.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Linda R Mona, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mr. Terence Breffni Moran, PMP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Kristen N Myers, PharmD, BCPS

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses: This presentation will discuss many medications and classes of medications. They will be discussed as part of de-prescribing efforts for inappropriate medications in the setting of SCI, and recommended alternatives. We have attempted to summarize medication classes where off label use MAY be discussed. Please note that none of these off-label uses of medications are being recommended, rather, these medications may have been prescribed for off label uses, and this may be discussed as part of the presentation. Benzodiazepines: anxiety, spasticity. Non-selective beta blockers: anxiety, postural orthostatic tachycardia syndrome. Alpha Blockers; lower urinary tract symptoms, chronic prostatitis, ureteral stent-related urinary symptoms. Fluoroquinolones: surgical prophylaxis, prostatitis, epididymitis, osteomyelitis. NSAIDs: acute gout flare.

Meghan O'Brien, MS, CCC-SLP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mr. Eric Ochmanek, BA

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. James Orengo, MD, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Yukina Ota, MS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Kaila Ott, M.S., ATP, RET

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Sangmi Park, OTR

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Stephane Philippe-Ratway, M.S.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mr. Dukens Pierre, RT

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Roni Pitts, OTR/L, OTD

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Jason Hendrik Raad, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Korren Rappisi, RRT BA

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mrs Jaime S Raymond, MPH

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Malcolm Reed, OTR/L

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Laura A Rice, Ph.D., MPT, ATP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mrs. Sarah Riley, R.N.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr John R Rinker, MD

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses I will discuss failed trials of various drugs used to treat multiple sclerosis including Cyclophosphamide, rituximab, laquinimod, tolebrutinib, opicinumab

Abigail Louise Ruppel, PT, DPT, NCS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Ms. Daniell S Ruth, MBA., MSN., RN

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Sunil Sabharwal, MD

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Shantanu A Satpute, M.S, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Alessandro Serra, M.D., Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses: Gabapentin, memantine, baclofen, 4-aminopyridine can be used outside their FDA label to treat nystagmus and other ocular oscillations

Dr. Babak Shadgan, MD, MSc Sports Med, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Nicole Sharf, M.A.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Afsaneh Shirani, MD, MSCI

- TG Therapeutics: I have received an honorarium for serving on the TG Therapeutics advisory board.
- Unapproved drug or product uses: One of the real-world cases I'll present during this meeting involves a patient who was prescribed teriflunomide off label for primary progressive multiple sclerosis.

Dr. Jo Ann Shoup, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Elizabeth Silbermann, MD, MCS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Jennifer Lynn Sippel, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Felicia Skelton, MD, MS

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Ms. Kelly Dolan Skinner, DNP, APRN, ANP-C, GNP-BC, CRRN, WCC, CFCN, CPHQ

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Ms. Alicia Sloan, MPH, MSW, LICSW

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Tammy Smith, MD., Ph.D.

- Alexion AstraZenica: research support
- No discussion of unapproved drug or product uses.

Dr. Staci Stark, RN

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Jessica Steinberg, B.S., M.S.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Ms. Rachel Szymanski, OTR/L, ATP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Samuel Talisman, OTD, OTR/L

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Lauren Van Valkenburgh, PT, DPT

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Mitchell Wallin, MD, MPH

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Clara Wan, M.D., MPH

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses I will discuss failed trials of various drugs used to treat multiple sclerosis including Cyclophosphamide, rituximab, laquinimod, tolebrutinib, opicinumab

Dr. Beth Whittington, M.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Catherine S Wilson, Psy.D., ABPP

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Ka-Ho Wong, MBA

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Lindsey Wooliscroft, M.D., M.Sc., M.C.R.

- No relevant financial relationships with ineligible companies to disclose.
- Unapproved drug or product uses I will discuss research regarding trans-magnetic stimulation for MS progression

Dr. Lynn Worobey, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Dr. Tommy Yu, M.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Manrui Zhang, Ph.D.

- No relevant financial relationships with ineligible companies to disclose.
- No discussion of unapproved drug or product uses.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies.

All relevant financial relationships for anyone involved with the content of this activity have been mitigated prior to the release of this program.

Physicians



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and PVA. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 22 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and PVA. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 22 *AMA PRA Category 1 Credits™*. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and PVA. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 22 *AMA PRA Category 1 Credits™*. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Occupational Therapists



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and PVA. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 22 *AMA PRA Category 1 Credits™*. Occupational Therapists should claim only the credit commensurate with the extent of their participation in the activity.

Nurses



Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and PVA. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 22 contact hours of continuing nursing education credit.

Criteria for Claiming CNE Credit: Participants must have registered and actively participated in the entire session for which credit is requested, attest to their attendance and complete the associated session evaluation.

Physical Therapists



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and PVA. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 22 *AMA PRA Category 1 Credits™*. Physical Therapists should claim only the credit commensurate with the extent of their participation in the activity.

Rehabilitation Counselors



This activity has been pre-approved by the Commission on Rehabilitation Counselor Certification (CRCC) for up to 22 contact hours.

CRCC pre-approval number: 60008005339

Social Workers

This program is Approved by the National Association of Social Workers (Approval # 886551225-2860) for 19 continuing education contact hours.

Pharmacists



AffinityCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based activity will provide a maximum of 22 contact hours for participants completing all CPE sessions. UANs are provided for each session.

Participant CE records will be electronically communicated to CPE Monitor. There is no cost to participate in this activity.

Pharmacist Learning Objectives

- Describe the existing literature on substance use among those with spinal cord injury
- Describe the frequency of substance use overall within the SCI respondent sample
- Identify key sexual and reproductive health challenges experienced by women with SCI/D, including menstrual management, contraceptive care, and perimenopausal/menopausal transitions, across the rehabilitation continuum.
- Describe the current clinical practices and therapeutic interventions reported by PTs that treat pALS
- Apply evidence-based interventions (pharmacologic, procedural, and surgical) to optimize outcomes in patients with NLUTD, with attention to safety and efficacy.
- Review the ethical and administrative principles to guide safe patient handling decisions.
- Evaluate barriers to bone health management and identify strategies health care professionals can use to improve access to preventative care and patient outcomes.
- Review best practices in management of SCI, MS, and ALS.
- Identify patterns of healthcare utilization and symptom clusters that may signal individuals at high risk for MS or related syndrome.
- Describe the importance of effective interdisciplinary communication and role sharing.
- Explain the association between cognitive decline in MS and its impact on functional status, community engagement, and quality of life.

Dietitians



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and PVA. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 22 *AMA PRA Category 1 Credits™*. Dietitians should claim only the credit commensurate with the extent of their participation in the activity.

Psychologists

AffinityCE is approved by the American Psychological Association to sponsor continuing education for psychologists. AffinityCE maintains responsibility for this program and its content. This activity provides up to 22 hours of CE Credit.

The instructional level of this activity is intermediate. The cost to participate in these CE sessions is included in the registration cost for the Program.

Psychologist Specific Learning Objectives

- Describe two different experiences of moral distress.
- Identify resiliency and trauma-informed skills to utilize in clinic-setting with caregivers.
- Identify differences between interdisciplinary and multidisciplinary care teams.
- Describe the utility of the Columbia Suicide Severity Rating Scale (C-SSRS) in ALS.
- Identify system redesign methods that support process improvement goals.
- Identify key gaps in early ALS care delivery that contribute to delayed intervention and crisis-driven acute care utilization among veterans.
- Identify patterns of healthcare utilization and symptom clusters that may signal individuals at high risk for MS or related syndrome.
- Describe the behavioral, emotional, and psychological experiences and needs of military and veteran connected young carers, including the impact of caregiving on development, education, and well-being.
- Identify different behavioral strategies to promote behavior change in MS.
- Recognize the role of the brain health clinic to help preventing MS progression.
- Discuss the behavioral and psychosocial implications of improved upper-extremity function, such as increased confidence, independence, and participation in daily activities, for individuals living with SCI.
- Discuss behavioral and psychosocial strategies such as motivational interviewing, resilience-building, and culturally responsive communication to enhance patient engagement and mental health after SCI.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Learning Accommodation and Accessibility Needs: Please notify conference staff at the time of registration for accessibility assistance.

Commercial Support

No commercial support was provided for this activity.

Participation Costs

The cost to participate in these CE sessions is included in the registration cost for the program.

How to Earn CE Credit

2026 Paralyzed Veterans of America (PVA) Healthcare Summit + Expo

Registration for the conference does not establish an account in the CE Center or automatically provide continuing education credit. You must sign into the CE Center site and evaluate the content of the activity to earn CE credit.

1. Go to pva.cds.affinityced.com.
2. Select the activity "2026 Paralyzed Veterans of America (PVA) Healthcare Summit + Expo."
3. Enter an e-mail address and password to begin setting up your profile. Select "I Forgot My Password" if you need to reset the password you set up.
4. Verify, correct, or add your information.
5. Proceed to complete the evaluation for each session you attended and attest to your attendance.
6. After evaluating all attended sessions, you must complete the Overall Evaluation to download your CE certificate.
7. Upon completing your evaluations, you can download your CE certificate. Your CE record will also be stored here for later retrieval.
8. U.S. based Pharmacists will need to supply their Date of birth, and NABP e-Profile ID. Pharmacist CE records will be electronically communicated to CPE Monitor.
9. The Web site is open for completing your evaluation for 30 days after the event, until September 25, 2026.
10. After the Web site has closed, you can come back to the site at any time to download your certificate, but you will not be able to add any evaluations.

Please send any CME inquiries or customer service requests to cds_support+PVA@affinityced.com.